Abcely's mission is to develop new innovative medical and pharmaceutical technologies in the field of the treatment of mucosal cancers, thus offering patients in therapeutic impasse a new solution based on a brand-new concept of immunotherapy in cancerology. The concept developed by Abcely is based on the use of a new class of orally active therapeutic molecules (IgA). Abcely is involved in all phases of development, from the identification of compounds of biological origin as potential active ingredients to the demonstration of their activity in the human clinic.
2, Rue Crucy
44000 Nantes, Pays de la Loire, FR
ABCELY a republié ceci
We are delighted to announce that ABCELY has been named a member of CLUB EXCELLENCE which brings together 2,000 exceptional leaders from the Bpifrance Network to cultivate their audacity and their ambitions. A big thank you to Bpifrance for this immense honor!
At the BIO International Convention in San Diego this week, Abcely made connections to transform therapeutic development for mucosal cancers and endometriosis. CSO Armelle Cuvillier , CTO Olivier Favre-Bulle and I have been meeting with potential partners and reconnecting with old friends. We are excited about the opportunities to advance our efforts in those areas and expand our highly innovative platform on orally-active secretory IgA. Stay tuned for more updates as we continue to push the boundaries of medical research. #Abcely. www.abcely.com
I have the great pleasure to announce that the Abcely website has been active since today. www.abcely.com
ABCELY a republié ceci
Abcely and the CRIBL laboratory (Control of Immune B cell Response and Lymphoproliferation, UMR CNRS7276 U1262 INSERM, University of Limoges, France) are pleased to announce the start of their collaboration to develop innovative in vivo study models for the generation and evaluation of the therapeutic efficacy of IgA class monoclonal antibodies. ABCELY's ambitious goal is to implement the methodologies and master the pre-industrial and industrial manufacturing processes of its first drug candidate: ABC101, an oral anti-carcinoembryonic antigen (CEA) IgA. CNRS - Centre national de la recherche scientifique Inserm Université de Limoges Paris Saclay Cancer Cluster Angels Santé GO CAPITAL Atlanpole Biotherapies Atlanpole #IgA #OralImmunotherapy #Oncology #Biotechnology #Innovation #Startup #Mucosalimmunity #lifescience #Digestivecancer #colorectalcancer
Abcely and the CRIBL laboratory (Control of Immune B cell Response and Lymphoproliferation, UMR CNRS7276 U1262 INSERM, University of Limoges, France) are pleased to announce the start of their collaboration to develop innovative in vivo study models for the generation and evaluation of the therapeutic efficacy of IgA class monoclonal antibodies. ABCELY's ambitious goal is to implement the methodologies and master the pre-industrial and industrial manufacturing processes of its first drug candidate: ABC101, an oral anti-carcinoembryonic antigen (CEA) IgA. CNRS - Centre national de la recherche scientifique Inserm Université de Limoges Paris Saclay Cancer Cluster Angels Santé GO CAPITAL Atlanpole Biotherapies Atlanpole #IgA #OralImmunotherapy #Oncology #Biotechnology #Innovation #Startup #Mucosalimmunity #lifescience #Digestivecancer #colorectalcancer
We are delighted having been selected by the Paris Saclay Cancer Cluster !! Thanks to all. https://lnkd.in/e-ZWvx_F
We are delighted to announce that 4 new projects have been selected in November to benefit from the PSCC Support ! Congratulations to them ! ABCELY, Brenus Pharma, Orakl Oncology and a start-up soon to be created. The PSCC provides a comprehensive offer to the most promising oncology projects : access to expertise, networking, technological platforms, data, financing, office/lab spaces.. Already 27 projects have been selected and supported. You develop an innovative solution for patients in oncology ? Come and join us ! Learn more about how to apply to the PSCC : https://lnkd.in/eTYvAZV7 #innovation #cancer #pscc #france2030
Nous venons d’actualiser notre page. Consultez notre page pour vous tenir au courant des dernières nouvelles.
Dernier round
Mise de fonds initiale2 558 494,00 $US